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Abstract 
Objective 
The Lewy body dementias (LBD, dementia with Lewy bodies and Parkinson’s 
disease dementia) are the second commonest cause of neurodegenerative dementia 
but remain under-recognised, with long delays from initial assessment to diagnosis. 
Whilst validated instruments have been developed for key symptoms there is no brief 
instrument for overall diagnostic assessment suitable for routine practice. We here 
report the development of such assessment toolkits. 
Methods 
We developed the LBD assessment toolkits in three stages. First we conducted a 
systematic search for brief validated assessments for key symptoms and combined 
these into draft instruments. Second we obtained feedback on acceptability and 
feasibility through two rounds of interviews with our Patient and Public Involvement 
group. This led to modification of the toolkits. Finally, we piloted the toolkits in a 
feasibility study in routine Dementia and Parkinson’s Disease services to produce 
final instruments suitable for routine clinical practice. 
 
Results 
Eleven clinicians, working in both dementia/memory assessment and Parkinson’s 
disease/movement disorder services consented to pilot the assessment toolkits and 
provide feedback on their feasibility. Clinicians worked in routine health service (not 
academic) settings and piloted the draft toolkits by integrating them into their regular 
clinical assessments. Feedback obtained informally, by written comments and 
through qualitative interviews led to modifications and production of final acceptable 
versions. 
Conclusions 
We were able to address an important need, the under-diagnosis of LBD, by 
developing toolkits for improving the recognition and diagnosis of the LBD which 
were acceptable to clinicians working in routine dementia and Parkinson’s disease 
services. 
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Introduction 
The accurate recognition of dementia and the diagnosis of subtype of dementia 
ensure appropriate management and are central to improving patient care for those 
with dementia. Dementia with Lewy bodies (DLB) is the second commonest cause of 
degenerative dementia in older people after Alzheimer’s disease(Stevens et al., 
2002). Dementia also develops in up to 80% of people with Parkinson's disease, 
(PDD)(Aarsland et al., 2003)]. Prevalence estimates from both clinical and 
epidemiological samples of PD subjects indicate that at least 30% of those with PD 
have dementia(Riedel et al., 2010), while longitudinal study shows that 80% of those 
with PD will eventually develop dementia(Aarsland et al., 2003). PDD and DLB 
together are known as Lewy body dementias (LBD) because they share common 
clinical features, have closely overlapping neurobiology and respond to similar 
management approaches(Aarsland et al., 2004). Taken together, LBD accounts for 
10-15% all cases of dementia(Stevens et al., 2002), affecting around 100,000  
people in the UK. While both DLB and PDD share the problems of under-recognition 
and inappropriate management, the reason for these problems differs between DLB 
and PDD.  
 
Despite the known prevalence of DLB, it has been estimated that only around one in 
3 cases are currently detected in routine care in the UK (Alzheimer Society, 2007); 
for every DLB case properly diagnosed another two are either not detected or 
misdiagnosed, usually as AD. Furthermore, the route to diagnosis for patients with 
DLB is often protracted with one US study reporting that half of the patients had 
more than 10 clinic visits before the correct diagnosis was made(Galvin et al., 
2010)]. There are several reasons for these difficulties with recognition including lack 
of assessment of key clinical symptoms such as hallucinations, fluctuation, and sleep 
disorder in dementia assessment services and the challenges in eliciting motor 
features of parkinsonism in those with dementia(Ballard et al., 1997).Changing 
practices in dementia assessment services also mean that initial assessments are 
often carried out by non-medical staff who are not able to perform neurological 
examinations.  
 
Improving the accuracy of detection and diagnosis of PDD raises related but also 
distinct issues. Although patients with Parkinson’s disease (PD) are often under 
regular follow-up in neurology or geriatric medicine services only around 1 in 3 of 
those with PDD are currently recognised and diagnosed(Dujardin et al., 2010), and 
usually late in their illness. Again, there are several reasons for missed and delayed 
diagnosis of PDD: 1) cognitive impairment develops insidiously and at a variable 
time after PD diagnosis; 2) initial symptoms such as fluctuation, attentional problems 
and hallucinations may be thought to be related to medication side effects; 3) there is 
a general lack of awareness of the benefits of diagnosing dementia and a reluctance 
of professionals to disclose the diagnosis; 4) cognition is often not routinely 
assessed in neurology and geriatric medicine clinics. As with DLB, the recognition of 
dementia in PD brings the clear management benefits recognised for all those with 
dementia, including allowing the prescription of anti-dementia medication, provision 
of support, education and advice, access to services, financial and other benefits 
and opportunities for future planning and attending to medico-legal issues(O'Brien et 
al., 2011). 
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Considerable progress has been made in developing quick and validated tools for 
the assessment of key clinical symptoms of LBD, e.g. the Lewy Body Composite 
Risk Score (LBCRS)(Galvin, 2015). However, there is no single, simple to administer 
toolkit which incorporates the range of clinical symptoms and which can be used by 
clinicians broadly, e.g. the LBCRS assumes clinical expertise not necessarily present 
in  the  staff carrying out assessments in many clinics and the LBCRS does not 
directly link to the diagnostic criteria for DLB. Hence a brief assessment toolkit is 
needed which is suitable for use in routine practice by all clinical staff. We report 
here the development of such toolkits as part of a feasibility study to improve the 
recognition and diagnosis of both DLB and PDD as part of the NIHR ‘Improving the 
diagnosis and management of neurodegenerative dementia of Lewy body type’ 
study (DIAMOND Lewy study). 
 
Methods 
 
We developed the LBD assessment toolkits in three stages. First we identified brief 
validated assessments for different symptoms and signs that are key to making a 
LBD diagnosis and then combined these into a pilot instrument. Second we obtained 
feedback on the acceptability and feasibility of the toolkit through interviews with 
patients, carers, clinicians and the programme Patient and Public Involvement (PPI) 
group. This was used to modify the toolkits prior to piloting. Finally, we piloted the 
toolkits in a feasibility study in Dementia and Parkinson’s Disease services and 
modified the instrument to a final acceptable version suitable for use in routine 
clinical practice. 
 
Development of Pilot Assessment Tools 
Clinical experts (AJT, JPT, IM, LA, DB, JOB) reviewed the published literature and 
supplemented this by their expert knowledge to identify available validated 
assessments instruments(Ballard et al., 1997; Boeve et al., 2011; Lee et al., 2014; 
Mosimann et al., 2008). Following funding, the DIAMOND Lewy Programme 
Management Group (PMG) first discussed the basic approach to the problem and, 
building on this evidence, concluded two different instruments would be needed, one 
for DLB and one for PDD. These would be matched to the international diagnostic 
criteria for DLB(McKeith et al., 2005) and PDD(Emre et al., 2007). The PMG 
identified appropriate components for each toolkit from the identified assessment 
instruments. 
 
For the DLB toolkit the aim was to improve identification of the core and suggestive 
diagnostic symptoms, since diagnosis of cognitive impairment and dementia in 
specialist dementia services is not a concern. There are six core and suggestive 
symptoms for diagnosing DLB. One is dopaminergic imaging, which would not form 
part of a clinical assessment tool, and another is neuroleptic sensitivity which can 
only be identified following exposure to antipsychotic drugs, which is now a rare 
event(Walker et al., 2014). Hence the focus was on assessment of the four 
remaining symptoms: persistent complex visual hallucinations, spontaneous 
cognitive fluctuations, spontaneous parkinsonism and REM sleep behaviour disorder 
(RBD). The following components of the instrument were identified: 
 
a) Cognitive fluctuation. Four questions to carers from the Dementia Cognitive 
Fluctuation Scale(Lee et al., 2014).   
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b) RBD. A single screening question to carers from the Mayo Sleep 
Questionnaire(Boeve et al., 2011). 
c) Visual hallucinations. Two core questions for patients and two for carers from the 
North East Visual Hallucinations Inventory(Mosimann et al., 2008). 
d) Motor features of parkinsonism: 5 items from the Unified Parkinson's Disease 
Rating Scale(Ballard et al., 1997). 
 
For the PDD tool, the aim was to improve identification of cognitive impairment and 
to facilitate matching of symptoms to the PDD diagnostic criteria(Emre et al., 2007). 
The Montreal Cognitive Assessment (MoCA) was identified as most appropriate for 
brief cognitive assessment in this context(Nasreddine et al., 2005). 
 
AT then put together the two instruments and after iteration with the rest of the PMG 
a draft version was sent to the PPI panel. The PPI panel, including patients and 
carers, then contributed comments and this feedback was incorporated into a 
revised version which was again commented on by the PPI members until a final 
agreed version and text was agreed for the pilot study. These two iterative rounds 
led to changes in wording of questions to try and improve clarity and the major 
change suggested was to separate the PDD tool into one version for use with carers 
and one for use with patients, based on how patients present to PD services where 
they may or may not have a carer present. After final iterations between PMG and 
PPI groups three final assessment toolkits were produced for the pilot and feasibility 
study (see appendix 1) 
 
Pilot and Feasibility of Assessment Toolkits 
A pilot and feasibility study of the assessment instruments was carried out within 
Gateshead Health NHSFT, a representative Trust which provides old age psychiatry 
(memory/dementia) services (OAP) and Parkinson’s disease (movement disorder) 
services. Following ethical and R&D approvals from Gateshead Health NHSFT, 
medical and nursing staff were identified in the OAP and PD services and given brief 
information about the study and brief training in using the assessment tools. The 
aims of the pilot was to ensure that the diagnosis tools were acceptable to staff and 
could be integrated into current assessment procedures in busy clinical services. 
Piloting was to include all subjects having first assessments for memory impairments 
and/or dementia due to possible Alzheimer’s disease or other causes in the OAP 
service and in the PD Service all those with PD where any cognitive impairment was 
suspected. The aim was to include at least four staff (doctors and nurses) in each 
service and at least 20 subjects per service. Completed assessment toolkits were 
kept by the research team with copies placed in the patient notes. 
 
Results 
 
Four OAP consultants and four Elderly Medicine PD clinicians (two specialist nurses, 
two consultants) agreed to take part initially. Three additional clinicians who were on 
leave or not initially working within the service were subsequently recruited (two 
specialist registrars within the OAP service and one consultant from the PD Service) 
to increase opportunities for accrual. 
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Patient recruitment 
The number of patients consenting for the use of the tool(s) by individual clinicians 
ranged from zero to seven. Two PD clinicians did not use the assessment tool (one 
clinician moved from the service soon after the pilot study started, the other felt it 
was not appropriate for any of their patients) but a later PD clinician did. All OAP 
clinicians used the assessment tool at least once. Clinicians working in old age 
psychiatry recruited more patients (a total of 19) than their colleagues in the PD 
service (a total of 7).  
The toolkits were used with patients with and without LBD (see Table 1).  One 
patient had diagnoses of both vascular dementia and PD and therefore the total 
number of diagnoses was 27. Patients with PD may be seen by the OAP service and 
the movement disorder service and during the study period one patient was seen by 
both services at different times and completed the appropriate assessment tool in 
each service.  
 
 
INSERT TABLE 1 HERE PLEASE 
 
 
Feedback and Modification of the assessment toolkits 
Feedback from clinicians was obtained in a number of ways: 
 Informal feedback to the local chief investigator (AT) and the research nurse 
 Written comments on completed assessment tools 
 Qualitative interviews (CB). 
For the patients none of the questions from the assessment toolkits stood out as 
being inappropriate or unclear. For clinicians, generally the tools were found to be 
straightforward to use, with the constraints being on time available within current 
service structures. The PD service in particular found it difficult to integrate a 
cognitive assessment into their initial patient assessment. The toolkits were regarded 
as helpful in encouraging the assessment of the relevant symptoms for diagnosis 
and useful in providing structure and a specific approach. 
Based on detailed feedback in these ways the pilot toolkits were modified as follows 
(final DLB and PDD Assessment Toolkits are in Appendices 2 and 3 respectively). 
PD clinicians felt it would be helpful to have questions on core and suggestive 
symptoms of DLB in the PDD toolkit and did not feel that in practice there was a 
need to have separate carer and patient versions of the PDD tool. Hence the revised 
final version for PD services (see Appendix 3) is titled “Assessment Toolkits for Lewy 
Body Dementia” and includes two toolkits, depending on whether the patient has 
longstanding PD and recent cognitive decline or whether the PD 
diagnosis/symptoms are recent, along with cognitive symptoms. A specific issue 
raised for RBD was what to do if no bed-partner was available to answer the RBD 
question. AT contacted Dr Brad Boeve (Mayo Clinic, Minnesota) who had developed 
the RBD instrument and was advised that a similar question can be used with 
patients who are mildly cognitively impaired about any known history of ‘acting out 
dreams’. This additional option was therefore included in the final versions. In the 
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pilot version of the PD toolkits the MOCA had been specified. However, PD nurses 
were not familiar with the MOCA, although they aimed to complete an MMSE 
annually with each patient, and clinicians suggested that it be clarified that other 
cognitive instruments could be used if these were preferred, which has been done in 
the final LBD toolkit. A third specific concern was that the wording, whilst clear, 
sometimes appeared prescriptive and seemed to not allow clinical judgement about 
the presence of symptoms, and so the wording has been changed at several points 
to make it clear that the questions in the toolkits are a guide and ultimately the 
presence of key symptoms, like final diagnoses, is a clinical judgement based on all 
available evidence. Several other more minor issues were raised about the layout 
and format which have been incorporated into the final versions of the toolkits, e.g. 
consistent use of tick boxes and an expanded list of diagnostic options for people 
with cognitive impairment. 
Thus following the pilot feedback led to changes in the assessment instruments. 
Specifically a single PD assessment toolkit was produced which included the 
questions from the DLB toolkit for identifying visual hallucinations, cognitive 
fluctuations and RBD. Wording was also changed as was some of the layout in 
response to comments.  
 
Discussion 
We were able to combine elements from validated symptom assessment instruments 
into Assessment toolkits for improving the diagnosis of DLB and PDD. These toolkits 
were developed to be aligned with the standard diagnostic criteria for these 
dementias(Emre et al., 2007; McKeith et al., 2005) and in our feasibility study proved 
to be broadly acceptable to clinicians in regular clinical services and easily integrated 
into routine care making them ‘invisible’ to patients during clinical assessments. The 
piloting of these toolkits identified a few key changes, such as the desire for a 
combined LBD toolkit for use with both patients and carers in PD services and the 
addition of an RBD question for use when no bed-partner is available.  
The study aimed to address the problem of inadequate recognition and diagnosis of 
both DLB(Galvin et al., 2010; Alzheimer Society, 2007) and PDD(Dujardin et al., 
2010) and self-consciously sought to build on existing evidence by utilising 
previously researched and validated instruments(Ballard et al., 1997; Boeve et al., 
2011; Lee et al., 2014; Mosimann et al., 2008). We did not therefore seek to assess 
the psychometric properties of the specific elements of the toolkits, rather we sought 
to address the need to combine these instruments into clinically useful and usable 
toolkits for clinicians working in dementia and PD services. Following this feasibility 
study the toolkits will require further testing in other clinical populations to examine if 
they do indeed improve the diagnosis of LBD. Although the absence of validation 
may be regarded as a limitation, the fact the components have been tested and 
validated previously provides some reassurance. The piloting of these toolkits in a 
single organisation may also be regarded as a limitation of this study. Finally whilst 
we had an adequate number of old age psychiatry clinicians using the toolkits we 
only had three PD clinicians. Whilst our study was deemed to have reached 
saturation we acknowledge that future assessments of these toolkits will require 
more PD clinicians. However, the aim was to improve utility of the instruments in 
routine dementia and PD services and the clinicians involved were not academics or 
researchers and are representative of clinicians in such services in the UK. 
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Furthermore, it was clear from the feedback that we had reached saturation, making 
it unlikely that involvement of additional clinicians would have contributed usefully to 
the study. Although the instruments were not themselves regarded as burdensome 
the intense pressure on clinicians’ time sometimes made it difficult for them to use 
them, raising questions about how current service designs might be hindering high 
quality diagnostic assessments. One consequence of such pressures is that nursing 
staff are often conducting parts of the clinical assessments in many services and in 
order to assess parkinsonism using require specialist training. 
In conclusion, we sought to address an important need with this study, namely the 
under-recognition and under-diagnosis of LBD in routine services. We have done 
this by developing brief and usable instruments which can be integrated into routine 
clinical practice. The pilot versions proved acceptable to clinicians and patients and 
we encourage the use of the final versions to improve the diagnostic rates of DLB 
and PDD. 
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Table 1 Diagnoses of participating patients 
 
 Possible/probable 
DLB 
Non-DLB - other 
diagnoses inc 
depression, 
Vascular 
Dementia, Mild 
Cognitive 
Impairment. 
PDD or PD-
MCI 
Parkinson’s 
disease  
 
Use of 
tool(s) 
5 12 2 8 
Qualitative 
interview 
3 2 0 1 
 
 
